

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
08 June 2023 (08.06.2023)



(10) International Publication Number
WO 2023/102469 A2

(51) International Patent Classification:

C12N 15/113 (2010.01) A61P 1/16 (2006.01)
A61K 31/713 (2006.01)

(21) International Application Number:

PCT/US2022/080736

(22) International Filing Date:

01 December 2022 (01.12.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/264,730 01 December 2021 (01.12.2021) US

(71) Applicant: **DICERNA PHARMACEUTICALS, INC.**
[US/US]; 75 Hayden Avenue, Lexington, Massachusetts
02421 (US).

(72) Inventors: **BROWN, Bob Dale**; c/o Dicerna Pharmaceu-
ticals, Inc., 75 Hayden Avenue, Lexington, Massachusetts
02421 (US). **DUDEK, Henryk**; c/o Dicerna Pharmaceu-
ticals, Inc., 75 Hayden Avenue, Lexington, Massachusetts
02421 (US). **SAXENA, Utsav**; c/o Dicerna Pharmaceuti-
cals, Inc., 75 Hayden Avenue, Lexington, Massachusetts
02421 (US). **HAN, Wen**; c/o Dicerna Pharmaceuticals, Inc.,
75 Hayden Avenue, Lexington, Massachusetts 02421 (US).

(74) Agent: **REID, Andrea L.C.** et al.; c/o Dechert LLP, One
International Place, 40th Floor, 100 Oliver Street, Boston,
Massachusetts 02110-2605 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,
SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: COMPOSITIONS AND METHODS FOR MODULATING APOC3 EXPRESSION

(57) Abstract: Oligonucleotides and compositions including the same are disclosed for inhibiting or reducing apolipoprotein C-III (APOC3) gene expression. Methods of making and using the oligonucleotides also are disclosed, particularly uses relating to treating diseases, disorders and/or conditions associated with APOC3 expression.

WO 2023/102469 A2